Piper Sandler downgrades Pulmonx stock to Neutral on growth concerns

Published 31/07/2025, 06:54
Piper Sandler downgrades Pulmonx stock to Neutral on growth concerns

Investing.com - Piper Sandler downgraded Pulmonx Corp . (NASDAQ:LUNG) from Overweight to Neutral on Thursday, while significantly reducing its price target to $2.50 from $9.00 following the company’s second-quarter report. The stock, which has declined over 53% year-to-date, is currently trading at $3.15. According to InvestingPro analysis, the company appears undervalued at current levels.

The research firm cited six consecutive quarters of deceleration in Pulmonx’s high-margin U.S. business, creating concerns about management’s ability to meet even its updated full-year outlook. While the company maintains an impressive 73.47% gross margin and achieved 19.84% revenue growth in the last twelve months, Piper Sandler expressed doubts about the company’s potential to return to 15-20%+ top-line growth.

While acknowledging value in Pulmonx’s differentiated technology and high gross margin percentage in the endobronchial valve (EBV) market, the firm highlighted emerging headwinds affecting procedure volume and revenue growth.

Piper Sandler also raised concerns that Pulmonx’s path to EBITDA breakeven appears more distant than previously estimated, potentially extending the timeline for profitability.

The downgrade included warnings that Pulmonx might need to secure additional financing within the next one to two years, which could potentially be unfavorable to existing shareholders. However, the company currently maintains a strong liquidity position with a current ratio of 4.97 and holds more cash than debt on its balance sheet.

In other recent news, Pulmonx Corp reported its earnings for the second quarter of 2025, showing a net loss of $0.38 per share. This result was slightly better than analysts’ expectations, which had anticipated a loss of $0.40 per share. The company also reported revenue of $23.9 million, exceeding the forecasted $23.47 million. These financial results indicate a positive performance relative to projections. There were no updates regarding mergers or acquisitions. Analyst firms have not recently upgraded or downgraded Pulmonx’s stock. The company’s financial results are the main focus of recent developments. No additional company news was reported.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.